Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Stealth Bio Raises $100 Million from China Investors for Mitochondrial Candidates

publication date: Jun 19, 2018

Stealth Biotherapeutics, a Boston a clinical-stage biopharma that targets mitochondrial dysfunction, completed a $100 million financing in two convertible note rounds led by Nan Fung Technology's Pivotal Beta. Stealth will use the proceeds to continue a Phase IIb clinical trial of Stealth's lead compound, elamipretide, in intermediate dry age-related macular degeneration. Founded in 2007, Stealth is working on treatments for mitochondrial diseases that remain unmet needs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital